Immatics (IMTX) Gains from Investment Securities (2020 - 2025)
Immatics recorded quarterly Gains from Investment Securities of -$1.2 million in Q4 2025, up 60.5% quarter-over-quarter from -$3.1 million in Q3 2025, and up 88.93% year-over-year from -$650624.8 in Q4 2024.
Immatics' Gains from Investment Securities history runs 5 years deep, the most recent figure standing at -$1.2 million for Q4 2025.
- In Q4 2025, Gains from Investment Securities rose 88.93% year-over-year to -$1.2 million; the TTM figure through Dec 2025 stood at -$10.1 million (up 27.95% YoY), while the FY2025 annual figure was -$10.4 million, up 26.04% from the prior year.
- Gains from Investment Securities came in at -$1.2 million for Q4 2025 at Immatics, up from -$3.1 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $18.5 million in Q1 2022 to a low of -$23.3 million in Q4 2021.
- A 4-year average of -$2.4 million and a median of -$2.3 million in 2022 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities surged 1165.71% in 2022 and plunged 742.74% in 2025, its largest moves.
- Immatics' Gains from Investment Securities stood at -$23.3 million in 2021, then soared by 133.49% to $7.8 million in 2022, then slumped by 242.22% to -$11.1 million in 2024, then surged by 88.93% to -$1.2 million in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$1.2 million, -$3.1 million, and -$646349.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.23 Mn |
| Dec 31, 2025 | -1.23 Mn |
| Sep 30, 2025 | -3.11 Mn |
| Sep 30, 2025 | -3.11 Mn |
| Jun 30, 2025 | -646,348.98 |
| Jun 30, 2025 | -646,348.98 |
| Mar 31, 2025 | -5.13 Mn |
| Mar 31, 2025 | -5.13 Mn |
| Dec 31, 2024 | -11.10 Mn |
| Dec 31, 2024 | -11.10 Mn |
| Sep 30, 2024 | -762,164.33 |
| Sep 30, 2024 | -762,164.33 |
| Jun 30, 2024 | -1.56 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | -608,362.59 |
| Mar 31, 2024 | -608,362.59 |
| Dec 31, 2022 | 7.81 Mn |
| Dec 31, 2022 | 7.81 Mn |
| Sep 30, 2022 | -5.91 Mn |
| Sep 30, 2022 | -5.91 Mn |
| Jun 30, 2022 | -2.97 Mn |
| Jun 30, 2022 | -2.97 Mn |
| Mar 31, 2022 | 18.55 Mn |
| Mar 31, 2022 | 18.55 Mn |
| Dec 31, 2021 | -23.31 Mn |
| Dec 31, 2021 | -23.31 Mn |
| Sep 30, 2021 | -6.43 Mn |
| Sep 30, 2021 | -6.43 Mn |
| Jun 30, 2021 | -3.28 Mn |
| Jun 30, 2021 | -3.28 Mn |
| Mar 31, 2021 | 1.47 Mn |
| Mar 31, 2021 | 1.47 Mn |
| Dec 31, 2020 | 5.51 Mn |
| Dec 31, 2020 | 5.51 Mn |
| Sep 30, 2020 | 15.37 Mn |
| Sep 30, 2020 | 15.37 Mn |